利福平作用機(jī)制 - Medchemexpress - MCE中國

1、Product Data SheetRifampicinCat. No.: HY-B0272CAS No.: 13292-46-1分式: CHNO分量: 822.94作靶點(diǎn): Bacterial; Influenza Virus作通路: Anti-infection儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 50 mg/mL (60.76 mM; Need ultrasonic)H2O : 0.1 mg/mL (insoluble)SolventMass1 mg 5

2、 mg 10 mgConcentration制備儲備液1 mM 1.2152 mL 6.0758 mL 12.1516 mL5 mM 0.2430 mL 1.2152 mL 2.4303 mL10 mM 0.1215 mL 0.6076 mL 1.2152 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲備液的保存式和期限：-80C, 6 months; -20C, 1 month。-80C 儲存時(shí)，請?jiān)?6 個(gè)內(nèi)使，-20C 儲存時(shí)，請?jiān)?1 個(gè)內(nèi)使。體內(nèi)實(shí)驗(yàn)請根據(jù)您的實(shí)驗(yàn)動物和給藥式選擇適當(dāng)?shù)娜芙獍?。以下溶解案都請先按?I

3、n Vitro 式配制澄清的儲備液，再依次添加助溶劑：為保證實(shí)驗(yàn)結(jié)果的可靠性，澄 的儲備液可以根據(jù)儲存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的作液，建議您現(xiàn)現(xiàn)配，當(dāng)天使； 以下溶劑前顯的百分 指該溶劑在您配制終溶液中的體積占；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的式助溶1. 請依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (3.04 mM); Clear solution; Need ultrasonic此案可獲得 2.5 mg/mL (3.04 mM) 的澄清溶液。以 1 mL 作液為

4、例，取 100 L 25.0 mg/mL 的澄 DMSO 儲備液加到 400 L PEG300 中，混合均勻；向上述體系中加50 L Tween-80，混合均勻；然后繼續(xù)加 450 L 理鹽定容 1 mL。2. 請依序添加每種溶劑： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/mL (3.04 mM); Clear solutionPage 1 of 2 www.MedChemE此案可獲得 2.5 mg/mL (3.04 mM，飽和度未知) 的澄清溶液。以 1 mL 作液為例，取 100 L 25.0 mg/mL 的澄 DMSO

5、儲備液加到 900 L 20% 的 SBE-CD 理鹽溶液中，混合均勻。BIOLOGICAL ACTIVITY物活性 Rifampicin種有效的譜抗素，可抵抗細(xì)菌病原體。Rifampicin 具有抗流感病毒活性。體外研究 Rifampicin (100 mg/mL) can block the functional activity of P-glycoprotein. Rifampicin is not a substract for P-glycoprotein. The mechanism of rifampicin resistance is unassociated with th

6、e functional activity of P-glycoprotein3.體內(nèi)研究 Rifampicin (200, 400 mg/kg) can induce fatty liver at high concentration1. Rifampicin (30 mg/kg, i.p.) treatment ofS464P biofilms in vivo results in a slight decline, but earlier rebinds in bioluminescence from these catheterscompared with the parental s

7、ignal, whereas rifampicin has no affect on bioluminescence in mice infected with mutantH481Y2.PROTOCOLAnimal Briefly, 1 cm Teflon catheter (14-gauge) carrying 104 cfu S. aureus, either the parental strain Xen 29 or the RifRAdministration 2 mutants S464P or H481Y, are implanted subcutaneously in grou

8、ps of nine mice per strain. One catheter segment isinserted on each side of each animal. Six days after the implantation of the catheters, five mice from each group aretreated with rifampicin at 30 mg/kg intraperitoneally in 0.1 mL saline, twice daily for four consecutive days. Theremaining four mic

9、e in each group are left untreated as controls. At various time points during the infection, the miceare anaesthetized using a constant flow of 1.5% isoflurane from the IVIS manifold, and imaged using an IVISImage System 100 Series. The bioluminescent signals (photons/s) emitted from the mice are an

10、alysed usingLivingImage software and plotted over the course of infection. The mice are sacrificed 20 days after infection (11days after final rifampicin treatment). The catheters are surgically removed and the bacteria are detached bysonication for determination of bacterial burdens on the catheter

11、s.MCE has not independently confirmed the accuracy of these methods. They are for reference only.戶使本產(chǎn)品發(fā)表的科研獻(xiàn) Phytomedicine. 2019 Mar 15;56:175-182. RSC Adv. 2019 May. Onco Targets Ther. 2018 Sep 17;11:5885-5894. Xenobiotica. 2019 Feb 11:1-33. Patent. US20200101105A1.See more customer validations on

12、HYPERLINK www.MedChemE www.MedChemEREFERENCES1. Piriou A, et al. Fatty liver induced by high doses of rifampicin in the rat: possible relation with an inhibition of RNA polymerases in eukariotic cells. ArchToxicol Suppl. 1979;(2):333-7.Page 2 of 3 www.MedChemE2. Yu J, et al. Monitoring in vivo fitne

13、ss of rifampicin-resistant Staphylococcus aureus mutants in a mouse biofilm infection model. J Antimicrob Chemother.2005 Apr;55(4):528-34. Epub 2005 Mar 2.3. Erokhina MV, et al. In vitro development of rifampicin resistance in the epithelial cells. Probl Tuberk Bolezn Legk. 2006;(8):58-61.4. Hamzehei M, et al. Inhibition of influenza A virus replication by rifampicin and selenocystamine. J Med Virol. 1980;6(2):169-74.McePdfHeightCaution: